Zag Bio Raises $80M Series A to Advance Thymus‑targeted Autoimmune Therapy
Cambridge‑based biotech Zag Bio announced an $80 million Series A financing to move its bispecific antibody platform targeting central tolerance into the clinic. The funding will support development of its lead program aimed at treating autoimmune diseases by rewiring the thymus. The round underscores investor confidence in the company’s novel approach to immune modulation.
Kailera Raises $1bn in Growth-Stage Funding Round
Kailera, a weight‑loss injectable maker, secured $1bn in a growth‑stage funding round from Atlas Venture, Bain Capital, CPP Investments, RTW Investments and Jiangsu Hengrui Pharmaceuticals. The capital will fuel its GLP‑1 product development and support an upcoming IPO in a...
Atavistik Bio Raises $160M in Series B Funding, Including $40M Extension
Atavistik Bio announced the completion of its Series B financing, raising a total of $160 million, with $120 million closed in December 2025 and a $40 million extension in March 2026. The capital will fund the development of its allosteric...
Biogen to Acquire Apellis Pharmaceuticals for $5.6B
Biogen announced on March 31, 2026 that it will acquire Apellis Pharmaceuticals for approximately $5.6 billion in cash, adding Apellis’ rare‑disease drugs Empaveli and Syfovre to its portfolio. The deal expands Biogen’s rare‑disease pipeline as its multiple‑sclerosis revenues decline.
Tempest Therapeutics Completes Acquisition of CAR‑T Assets From Factor Bioscience
Tempest Therapeutics announced the completion of its strategic acquisition of a portfolio of dual‑targeting CAR‑T assets from Factor Bioscience Inc. The all‑stock transaction adds next‑generation CAR‑T candidates, including TPST‑2003, to Tempest’s pipeline. Financial terms were not disclosed.
Kailera Therapeutics Files IPO to Fund Dual GLP-1/GIP Obesity Drug Development
Clinical-stage biotech Kailera Therapeutics filed its IPO paperwork with the SEC on March 29, 2026, seeking a Nasdaq listing under the ticker KLRA. The filing does not disclose the number of shares or proceeds, but the company plans to use...
Kyntra Bio Completes Sale of FibroGen China to AstraZeneca
Kyntra Bio announced the completion of the sale of its FibroGen China assets to AstraZeneca, enabling full repayment of its senior secured term loan and extending its cash runway into 2028.
Eli Lilly Commits $2.75B to Insilico Medicine for AI‑discovered Drug Candidates
On March 29, Eli Lilly announced a $2.75 billion corporate investment in Insilico Medicine, paying $115 million upfront and tying the remaining $2.63 billion to milestones and royalties. The deal grants Lilly global rights to develop and commercialize oral therapeutics discovered by Insilico’s AI...
Ysios Capital Launches $110M InceptionBio Fund to Build Biotech Companies
Spain’s largest life‑sciences VC, Ysios Capital, announced the launch of InceptionBio, a $110 million fund dedicated to creating biotech companies from university spin‑outs. The fund, anchored by Spain’s Centre for Technological Development and Innovation (CDTI), aims to establish at least three...
PetaSight Acquires Babbage Insight Two to Expand AI‑Led Life Sciences Research Platform
PetaSight Inc., a provider of an AI‑led operating system for life‑sciences primary market research, announced the acquisition of Babbage Insight Two Inc., a New York‑based developer of patented algorithms and data insight engines. The undisclosed deal will expand PetaSight’s platform...
VERIGRAFT Secures $10M Financing From Existing Investors to Launch Pivotal Phase II/III Trial
Swedish biotech company VERIGRAFT announced it has raised $10 million from existing investors to fund the initiation of a pivotal Phase II/III trial of its personalized tissue‑engineered vein (P‑TEV) for chronic venous insufficiency. The financing will support trial sites in...
Immutrin Secures $87M Series A to Advance ATTR‑CM Antibody Therapy
U.K.-based biotech Immutrin raised $87 million in a Series A round led by Frazier Life Sciences, with participation from Qiming Venture Partners, F‑Prime, SR One, Cambridge Enterprise Ventures and Cambridge Innovation Capital. The capital will fund the development of its lead antibody...
Cauldron Ferm Raises $13.25M in Series A2 Round Led by Main Sequence Ventures
Cauldron Ferm announced a $13.25 million Series A2 financing round led by Main Sequence Ventures, with participation from Horizons Ventures, NGS Super and SOSV. The funding will be used to scale its hyper‑fermentation technology for protein and fat production. The round...
Sanofi Invests $180M in T-Cell Engager Startup Kali
Sanofi announced a $180 million investment in California-based T-cell engager startup Kali, part of a larger deal valued at $1 billion. The funding will support Kali's development of next-generation T-cell therapies and marks Sanofi's renewed focus on the T-cell engager...
Gilead Sciences to Acquire Ouro Medicines in over $2 Billion Buyout
Gilead Sciences announced it will acquire privately held biotech Ouro Medicines for more than $2 billion, adding the experimental antibody OM336 to its immunology pipeline. The deal expands Gilead’s portfolio of autoimmune therapies as it seeks growth beyond its HIV...
Leyden Labs Raises €50M in European Funding Round
Leyden Labs, a biotech developing an intranasal antibody spray for flu protection, announced a recent €50 million European funding boost. The round will support further development and commercialization of its mucosal protection platform. The announcement was highlighted in a podcast interview...
Novartis to Acquire Experimental Breast Cancer Drug From Synnovation Therapeutics for $2B
Novartis announced it will acquire an experimental breast cancer drug from Delaware-based Synnovation Therapeutics in a deal valued at $2 billion upfront. The acquisition expands Novartis’s oncology pipeline and reflects its commitment to advancing cancer therapies. The transaction was reported on...
Earendil Labs Raises $787M in Private Funding
US-headquartered, China-rooted biotech Earendil Labs announced it has raised $787 million in private funding to expand its AI-driven drug discovery platform, which already supports a pipeline of over 40 programs. The capital will be used to accelerate development and position...
Novartis Spin‑out Atrium Therapeutics Launches with $270M Funding
Atrium Therapeutics, a spin‑out from Novartis‑owned Avidity Biosciences, has launched as an independent, publicly traded company focused on RNA therapeutics for rare genetic cardiomyopathies. The company secured $270 million in funding and entered a licensing agreement with Novartis for its RNA‑targeting...
R1 Therapeutics Raises $77.5M Series A to Advance Kidney Disease Drug
R1 Therapeutics announced an oversubscribed $77.5 million Series A round to advance its first‑in‑class hyperphosphatemia treatment for chronic kidney disease. The round was co‑led by Abingworth, F‑Prime and DaVita Venture Group. The funding will support global development, including a Phase 2b study of...
Crossbow Therapeutics Raises $77M in Series B Funding
Crossbow Therapeutics announced a $77 million Series B financing co‑led by Taiho Ventures and Arkin BioCapital, with participation from MPM BioImpact, Pfizer Ventures, Polaris Partners and other investors. The capital will fund the development of its TCR‑mimetic antibody candidates, including lead drug...
Virdalis Raises $700K Pre‑seed Round Led by Wavemaker Impact
Singapore‑based biotech startup Virdalis closed a $700,000 pre‑seed round led by venture builder Wavemaker Impact to scale its duckweed‑derived protein for animal feed. The funding will support pilot production, talent hiring, and commercial agreements across Southeast Asia, highlighting investor interest...
AstraZeneca Acquires FibroGen China From Kyntra Bio
Kyntra Bio completed the sale of its FibroGen China assets to AstraZeneca, enabling repayment of its senior secured term loan and extending its cash runway. The transaction was announced during Kyntra Bio's Q4 2025 earnings call on March 16, 2026.
MBX Biosciences Raises Additional Capital via At‑the‑market Program
MBX Biosciences, a clinical‑stage biopharmaceutical firm, reported its 2025 financial results and announced that it raised additional capital through its at‑the‑market program, boosting cash and investments to roughly $459.1 million. The funding will support its endocrine and metabolic disease pipeline through...
Clene Inc Raises over $28M in Oversubscribed Registered Direct Offering
Clene Inc announced it raised more than $28 million through an oversubscribed registered direct offering, boosting its cash balance to $5.2 million as of Dec. 31, 2025 and supporting operations into 2027. The fundraising was disclosed in the company's full‑year...
Deeptech Startup metaBIX Raises $1.3M in New Funding Round
Uruguayan deeptech startup metaBIX Biotech raised $1.3 million from Dalus Capital and EWA Capital, with participation from existing investors TheBoard Peru, Angel Hub, AIR Capital and Danta Fund. The capital will fund commercial expansion in Brazil and scaling of its AI‑driven...
Europa Biosite's Cambridge Bioscience Acquires UK Distributor Stratech Scientific
Europa Biosite announced that its UK subsidiary Cambridge Bioscience has acquired Stratech Scientific Limited, a long‑established UK life‑science distributor. The deal expands Europa Biosite’s product catalogue and strengthens its reach across UK academic and biopharma research communities. Financial terms were...
Enodia Therapeutics Acquires Kezar Life Sciences' Sec61 Assets for Up to $127M
Enodia Therapeutics announced it has acquired the Sec61‑based discovery and development assets of Kezar Life Sciences. The transaction includes an upfront payment of $1 million and potential milestone payments up to $127 million, plus royalties, bolstering Enodia’s targeted protein degradation platform and...
Mycoverse Raises €2.4M Pre‑seed Round Led by Future Food Fund and HTGF
Danish agritech startup Mycoverse announced the closing of a €2.4 million pre‑seed round to develop AI‑driven fungal biocontrol solutions for potato late blight. The round was co‑led by Future Food Fund and High‑Tech Gründerfonds, with participation from PINC, the venture arm...
MindImmune Therapeutics Secures $5M Funding From ADDF for Alzheimer’s Immunotherapy
Cambridge‑based biotech MindImmune Therapeutics announced a $5 million investment from the Alzheimer’s Drug Discovery Foundation to advance its lead candidate MITI‑101, an antibody targeting peripheral immune pathways in Alzheimer’s disease. The funding will support IND‑enabling studies and early‑stage clinical development, building...
BioInnovation Institute Funds 11 Life‑science Startups with €500k Convertible Loans Each
Copenhagen‑based BioInnovation Institute announced that its Venture Lab programme will support 11 early‑stage life‑science startups, each receiving a €500,000 convertible loan and access to labs, mentorship and its investor network. The 12‑month programme aims to accelerate commercialization of technologies in...
SignaCor Therapeutics Raises €288k From Zinc in €1.1M Seed Round
Belfast‑based healthtech startup SignaCor Therapeutics secured a €288k investment from venture capital firm Zinc, part of a €1.1 million seed round expected to close in April. The funding will support Phase 2a trial plans and regulatory strategy for its first‑in‑class treatment for...
Cytotrait Secures £3M Seed Funding to Advance Agricultural Gene-Editing Platform
Cytotrait, a University of Manchester spinout, closed a £3 million seed round led by Northern Gritstone with participation from UK Innovation & Science Seed Fund and Northern Universities Ventures Fund. The capital will expand its MOSS platform for organelle gene editing...
Swiss Rockets Acquires Complete Genomics
Swiss Rockets, a Basel‑based company, announced the acquisition of Complete Genomics, taking over its CoolMPS technology and key personnel while retaining the Complete Genomics brand. The deal aims to shield the genomics business from US regulatory concerns and includes royalty...
Prolium Bioscience Raises $50M in Series A Backed by RTW Investments
Prolium Bioscience Inc., a biotech startup developing T cell engagers, announced it has secured $50 million in a Series A round led by RTW Investments. The funding will support development of its TCE platform for multiple immunology indications.
Servier to Acquire Day One Biopharmaceuticals for $2.5B
French pharmaceutical group Servier announced a $2.5 billion all‑cash acquisition of U.S. biopharma Day One Biopharmaceuticals. The tender offer at $21.5 per share represents a 68.23% premium and is expected to close in Q2 2026.
Merck Exercises Option to License Evaxion's EVX‑B3 Infectious Disease Vaccine Candidate
Merck (MSD) exercised its option to acquire the EVX‑B3 infectious disease program from Evaxion A/S, marking the company's first in‑licensing of an AI‑discovered vaccine candidate. The agreement was announced during Evaxion's Q4 2025 earnings call.
Cognito Therapeutics Secures $105M Series C to Advance At‑Home Alzheimer’s Therapy
Cognito Therapeutics announced the closing of an oversubscribed $105 million Series C round led by Morningside Ventures, IAG Capital Partners and Starbloom Capital, with participation from Apollo Health Ventures and Benvolio Group. The funding will support a pivotal data readout, regulatory filing...
Kvantify Secures €7M Funding to Scale Quantum Drug Discovery Platform
Kvantify announced the second close of its funding round, bringing total capital raised to €7 million ($8.1 million) from the European Innovation Council Fund and Delphinus Venture Capital. The funding will accelerate the commercialization of its hybrid quantum‑classical software stack, Qrunch, for...
Teva Secures $400M Funding From Blackstone Life Sciences
Teva Pharmaceutical announced a $400 million financing from Blackstone Life Sciences to advance duvakitug, a Sanofi‑partnered TL1A blocker for inflammatory bowel disease. The investment will be disbursed over four years, with Blackstone receiving regulatory milestones and low‑single‑digit royalties on worldwide sales.
Antiverse Raises $9.3M Series A Led by Soulmates Ventures
Antiverse, an AI-driven antibody design company, announced a $9.3 million Series A round led by Soulmates Ventures, with participation from Innovation Investment Capital, DOMiNO Ventures, DBW, Kadmos Capital and i&i Biotech Fund. The funding brings total capital to over $20 million and will...
Gyre Therapeutics to Acquire Cullgen in $300M All‑Stock Deal
Gyre Therapeutics announced an agreement to acquire Cullgen in an all‑stock transaction valued at approximately $300 million, making Cullgen a wholly‑owned subsidiary upon completion in Q2 2026. The combined biopharma company will integrate US and China capabilities across discovery, manufacturing and commercialization,...
Scholar Rock Secures $550M Debt Facility From Blue Owl Capital
Scholar Rock Holding Corp announced it has secured a new debt facility of up to $550 million from Blue Owl Capital. The facility includes $100M drawn to refinance existing debt, $100M available for draw in Q1, $150M contingent on FDA...
Candid to Acquire Rallybio in Reverse Merger, Taking Company Public
Candid Therapeutics announced a reverse merger with Rallybio, creating a publicly traded company under the Candid name and ticker CDRX. The boards of both companies approved the transaction, which is expected to close in mid‑2026. The deal includes a $505 million...
Alveus Therapeutics Secures $37M Series A Extension Funding
Alveus Therapeutics Inc., a clinical‑stage biotech firm, closed a $37 million Series A extension round. The round was led by Jeito Capital and Novo Holdings, with participation from New Rhein Healthcare Investors, Andera Partners, Omega Funds, Sanofi Capital, Kurma Partners, Avego BioScience...
Kairos Pharma Signs Binding Agreement to Acquire Exclusive Worldwide Rights to CL‑273 From Celyn Therapeutics
Kairos Pharma announced it has signed a binding agreement to acquire the exclusive worldwide rights to the AI‑designed pan‑EGFR inhibitor CL‑273 from Celyn Therapeutics, a biotech backed by OrbiMed and Torrey Pines Investment. The acquisition expands Kairos’s oncology pipeline and...
Zura Bio Raises $144M in Public Offering to Advance Autoimmune Drug Pipeline
Zura Bio, a clinical‑stage biotechnology firm, completed a $144 million public offering of Class A ordinary shares and pre‑funded warrants, with underwriters fully exercising their option for additional shares. The proceeds will fund Phase 2 trials for its lead candidate tibulizumab and support...
Natera Acquires Foresight Diagnostics to Boost Ultra‑Sensitive MRD Testing
Natera announced the acquisition of Foresight Diagnostics during its Q4 2025 earnings call on Feb. 26, 2026. The deal adds Foresight's phased‑variant technology to Natera's Signatera platform, enabling detection below one fragment per 10 million normal copies. Financial terms were not...
Tamarind Bio Raises $12M Series A to Build AI Operating System for Biotech
Biotech AI infrastructure startup Tamarind Bio announced a $12 million Series A round led by Dimension Capital, bringing total funding to $13.6 million. The capital will fund headcount expansion and further development of its AI operating system for drug discovery labs.
Asahi Kasei to Acquire German Biotech Aicuris for €780M
Japanese drugmaker Asahi Kasei announced it will acquire German biotech Aicuris for €780 million, gaining its antiviral therapy pritelivir targeting HSV. The deal expands Asahi Kasei's anti‑infectives portfolio and supports its goal of reaching JPY 300 billion in pharma sales by 2030.